Sironax Reached Enrollment Milestone for Obesity Trial
The Phase 2 study of SIR4156 alongside semaglutide is now halfway to its total participant enrollment goal.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Do you trust that new medical treatments will effectively improve long-term obesity and metabolic health?
Sironax has reached approximately 50 percent of its targeted patient enrollment for the Phase 2 FORGE-LM clinical trial. This study evaluates the combination of the investigational drug SIR4156 with semaglutide in adults with obesity.
Why it matters
The trial explores whether restoring NAD+ metabolism through this combination therapy may offer potential benefits for those managing obesity. Preclinical research suggests this mechanism could address underlying metabolic factors, though clinical effectiveness remains to be determined.
The FORGE-LM study is a double-blinded, randomized, placebo-controlled, parallel-group trial. It is currently measuring the impact of SIR4156, an orally active allosteric NAMPT activator, in combination with semaglutide for adults with obesity.
The players
Sironax
A Waltham-based biotechnology company focused on developing therapies for metabolic and neuromuscular diseases by targeting cellular metabolism.
The details
SIR4156 functions as an allosteric NAMPT activator, a compound designed to influence the body's nicotinamide adenine dinucleotide (NAD+) metabolism. By combining this treatment with semaglutide, researchers aim to assess changes in body fat mass and body composition. The trial also monitors secondary outcomes including lean mass, pharmacokinetics, and the tolerability of the drug combination.
Timeline
October 13, 2026: Sironax announced the 50 percent enrollment milestone for the study.
Health Landscape
This trial follows broader research into NAD+ metabolism as a potential driver for metabolic health. It represents an evolving effort to investigate combination therapies that may complement existing weight-management standards.
As this is a Phase 2 trial, the study is still in the experimental stages and not yet available for general clinical use. Patients with obesity should continue to discuss approved treatment options and weight management strategies with their primary care physician.
The takeaway
The FORGE-LM trial is investigating whether the NAMPT activator SIR4156 can enhance the effects of semaglutide on body composition. Keep informed about clinical trial developments by speaking with your healthcare provider about whether current research reflects your personal health needs.
Further reading
Learn more about the latest research in this area by visiting our Weight Loss section.
Live Poll
Do you trust that new medical treatments will effectively improve long-term obesity and metabolic health?
